Telotristat etiprate - Lexicon Pharmaceuticals

Drug Profile

Telotristat etiprate - Lexicon Pharmaceuticals

Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Xermelo

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 01 Nov 2018 Lexicon Pharmaceuticals plans a clinical trial for Cancer, including Biliary tract cancer, in the fourth quarter of 2018
  • 16 Oct 2018 Updated efficacy and adverse events data from the phase III TELECAST and TELESTAR trials in Malignant carcinoid released by Ipsen Biopharmaceuticals
  • 16 Oct 2018 Registered for Malignant carcinoid syndrome (Adjunctive treatment, Treatment-experienced) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top